Novo Nordisk A/S $NVO Shares Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 77.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,340,858 shares of the company’s stock after acquiring an additional 584,275 shares during the period. Rockefeller Capital Management L.P.’s holdings in Novo Nordisk A/S were worth $68,223,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of NVO. Capital International Investors boosted its stake in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Loomis Sayles & Co. L P increased its stake in shares of Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after purchasing an additional 969,916 shares during the period. Franklin Resources Inc. increased its stake in shares of Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after purchasing an additional 717,719 shares during the period. Morgan Stanley raised its holdings in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after buying an additional 428,660 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after buying an additional 4,836,285 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.0%

Shares of NYSE:NVO opened at $43.20 on Friday. The company has a 50 day moving average of $42.92 and a 200-day moving average of $45.85. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market cap of $192.89 billion, a P/E ratio of 10.14, a P/E/G ratio of 3.86 and a beta of 0.78. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $74.38.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. As a group, analysts anticipate that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NVO. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research report on Tuesday, March 3rd. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a report on Tuesday, March 10th. Finally, Sanford C. Bernstein started coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.